The U.S. Centers for Disease Control and Prevention said on Friday it had recommended Moderna’s COVID-19 vaccine for children and adolescents aged 6 to 17, allowing a rollout of the shots to begin for that age group.
The United States has already delivered more than 4 million doses of COVID-19 vaccines for children under 5 years old to sites that will administer the shots, a Department of Health and Human Services (HHS) spokesperson said on Thursday.
COVID-19 vaccines that specifically target the Omicron and other variants are under development, Pfizer Inc.’s chief executive said on Wednesday, adding that the company will be able to quickly adapt shots as the novel coronavirus mutates.
The United States has begun distributing COVID vaccines for children as young as six months around the country, and availability of the shots will improve in the coming days, according to White House COVID-19 response coordinator Dr. Ashish Jha.
The rollout in the United States this week of COVID vaccines for children as young as six months is likely to start slowly, and then pick up in the coming days, according to White House COVID-19 response coordinator Ashish Jha.
The U.S. Centers for Disease Control and Prevention on Saturday recommended COVID-19 vaccines for children as young as six months, allowing a nationwide rollout to start next week.
Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, the Denmark-based biotech company’s COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech’s mRNA-based vaccine.
On Friday, the World Trade Organization approved vaccine patent waivers to increase the availability of COVID-19 vaccines to lower-income countries.
Advisers to the U.S Food and Drug Administration on Wednesday unanimously recommended the agency authorize COVID-19 vaccines from Moderna Inc. and Pfizer Inc./BioNTech SE for millions of the youngest American children.
Although a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe — Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford — a number of companies are continuing to develop vaccines in hopes they can be used as booster shots.